Skip Navigation

Phase I/II Open-Label Study to Evaluate the Safety and Preliminary Efficacy of Mrx0518 in Combination with Pembrolizumab in Patients with Non-Small-Cell Lung Cancer, Renal Cell Carcinoma, Bladder Cancer, and Melanoma Who Have Progressed on PD-1 Inhibitors

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT03637803

Study #:
STUDY00145409

Start Date:
Jul 28, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03637803

View Complete Trial Details & Eligibility at ClinicalTrials.gov